The U.S. National Institutes of Health has granted Israel’s Pluri (previously Pluristem) $4.2 million to develop its PLX-R18 (see here) as a treatment for Hematopoietic Acute Radiation Syndrome – a deadly disease that can result from nuclear disasters and radiation exposure.
https://pluri-biotech.com/wp-content/uploads/2023/07/1689056470_PLUR_NIAID_ARS_PR_FINAL-2.pdf
https://pluri-biotech.com/wp-content/uploads/2023/08/Pluri_PR_re_BMT_Article_FINAL_accessible.pdf